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Abstract
HIV-1-positive individuals on successful antiretroviral therapy (ART) are reported to have
higher rates of age-associated non-communicable comorbidities (AANCCs). HIV-associ-
ated immune dysfunction has been suggested to contribute to increased AANCC risk. Here
we performed a cross-sectional immune phenotype analysis of T cells in ART-treated HIV-
1-positive individuals with undetectable vireamia (HIV-positives) and HIV-1-negative individ-
uals (HIV-negatives) over 45 years of age. In addition, two control groups were studied: HIV
negative adults selected based on lifestyle and demographic factors (Co-morBidity in Rela-
tion to AIDS, or COBRA) and unselected age-matched donors from a blood bank. Despite
long-term ART (median of 12.2 years), HIV-infected adults had lower CD4+ T-cell counts
and higher CD8+ T-cell counts compared to well-matched HIV-negative COBRA partici-
pants. The proportion of CD38+HLA-DR+ and PD-1+ CD4+ T-cells was higher in HIV-positive
cohort compared to the two HIV-negative cohorts. The proportion CD57+ and CD27−CD28−
cells of both CD4+ and CD8+ T-cells in HIV-positives was higher compared to unselected
adults (blood bank) as reported before but this difference was not apparent in comparison
with well-matched HIV-negative COBRA participants. Multiple regression analysis showed
that the presence of an increased proportion of terminally differentiated T cells was strongly
associated with CMV infection. Compared to appropriately selected HIV-negative controls,
HIV-positive individuals on ART with long-term suppressed viraemia exhibited incomplete
immune recovery and increased immune activation/exhaustion. CMV infection rather than
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treated HIV infection appears to have more consistent effects on measures of terminal dif-
ferentiation of T cells.
Introduction
Antiretroviral therapy (ART) for human immunodeficiency virus type 1 (HIV-1) infection has
dramatically reduced AIDS-associated morbidity and mortality [1–3]. However, HIV-1-posi-
tive individuals on successful ART are reported to have higher rates of age-associated noncom-
municable comorbidities (AANCCs) than the general population [3–7]. Several contributing
factors have been implicated, including ART toxicity, chronic immune activation, immune
dysfunction and a higher prevalence of traditional risk factors [8, 9]. Interestingly, immuno-
logical alterations observed during treated HIV-1 infection reflect those observed in the gen-
eral population during aging [7, 10–12]. These include high levels of soluble inflammatory and
coagulation related proteins, high levels of T cell activation, high levels of T cell exhaustion,
low levels of naïve T cells and an extensive proliferative history of CD8 T cells [13–18].
Together, these age-associated immunological alterations are referred to as immune senes-
cence [19, 20], although the precise definition and clinical significance of this syndrome
remains controversial [4, 21, 22].
The immune senescent phenotype was first reported in a group of elderly adults who pro-
gressed more rapidly [23]. Subsequent work suggested that chronic viral infections such as
cytomegalovirus (CMV), hepatitis B virus (HBV), hepatitis C virus (HCV) and HIV, contrib-
ute to the development of this phenotype [8, 13, 15, 24–27]. Indeed, CMV infection is also
associated with low CD4:CD8 ratios, increased systemic inflammation and increased expan-
sion of terminally differentiated and senescent T cells [13, 15, 28, 29]. CMV prevalence is
extremely high in HIV-positive individuals and therefore CMV infection may well contribute
to the immune senescent phenotype observed in HIV-positive individuals. Recently, we dem-
onstrated that levels of terminal differentiation of T cells and immune senescence did not dif-
fer between HIV-positive individuals on ART and HIV-negative controls with comparable
age, lifestyle and demographic characteristics [30], findings which contrasted with those from
other studies [13–16]. To increase our understanding of these findings, we analysed the effect
of HIV-1 and CMV infection on T cell activation, exhaustion and terminal differentiation of T
cells in HIV-1-positive individuals with suppressed viraemia on ART (HIV-positive), HIV-
1-negative individuals (HIV-negative) comparable regarding most lifestyle and demographic
factors derived from the Co-morBidity in Relation to AIDS (COBRA) cohort, and age-
matched unselected blood bank donors (referred in the tables as BBD). Notably, these blood
bank donors are at lower risk of acquiring blood borne infections than the general population
but often used as a control group for comparative studies.
Materials and methods
Subjects
Study subjects other than the bloodbank donors participated in an ongoing European Com-
mission-funded project known as COBRA (Co-morBidity in Relation to AIDS). COBRA is a
detailed, prospective evaluation of the burden of AANCC among 134 HIV-1-positive patients
on ART and 79 appropriately chosen non-infected controls who have comparable socio-demo-
graphic and behavioral (risk) factors. COBRA aims to provide a robust estimate of the effect of
treated HIV infection on the prevalence, incidence and age of onset of AANCC. Furthermore,
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COBRA aims to clarify the pathogenic mechanisms underlying this causative link, including
the possible induction of an inflammation-associated accelerated ageing phenotype. Exclusion
criteria were: age under 45 years, and self-reported current intravenous drug use (in the past
six months), daily use of recreational drugs (with the exception of cannabis), and excess alco-
hol intake (>48 units per week). All HIV-positive participants were required to be on ART
and to have had undetectable plasma HIV RNA (<50 copies/mL) for12 months prior to
enrolment. Participants were recruited from two study sites: London and Amsterdam. For this
immunological study, 40 HIV-positive and 40 HIV-negative participants were randomly
selected with equal numbers in each of the following age-groups (45–50, 51–55, 56–60, 61–65,
66–70, and 70+), except for the oldest age category in which only a few individuals were avail-
able. Materials from blood bank donors were obtained from the Dutch national blood bank in
Amsterdam, the Netherlands (www.sanquin.nl). Blood bank donors (median: 58, IQR: 52.0–
65.0) were matched for age with the HIV-positive (Median: 58.5, IQR: 53.5–63.5) and HIV-
negative (median: 59.0, IQR: 53.0–64.5) COBRA participants and selected in such a way that
the different age categories in the COBRA, except for the category of 70+, were equally repre-
sented. Blood bank donors from the Netherlands are actively screened for HIV, Hepatitis B,
Hepatitis C, syphilis, and HTLV infection. Individuals aged above 70 years or individuals that
display high risk behavior for blood born infections are excluded from blood donation. Of
note, blood bank donors infected with HBV but who cleared the infection documented by an
anti-HBs antibody titer of at least 200 IU/L or blood bank donors that have been vaccinated
against HBV are not excluded from blood donation.
Ethics statement
This study has been conducted in accordance with the ethical principles set out in the declara-
tion of Helsinki and was approved by the institutional review board of the Academic Medical
Center (AMC) (NL 30802.018.09), the London (Stanmore) Research Ethics Committee (REC)
(13/LO/0584), and the Ethics Advisory Body of the Sanquin Blood Supply Foundation in
Amsterdam. Written informed consent was obtained from all participants.
T cell phenotyping and flow cytometry
Cryopreserved PBMC were thawed and cell viability was analysed by trypan blue staining and
for FACS analysis cell viability was required to be>75%. PBMC were stained with monoclonal
antibodies for 30min at 4˚C in the dark, to determine expression levels of different T-cell
surface molecules. T cell differentiation was defined as the proportion of naïve (CD45RA+
CD27+CCR7+), central memory (CD45RA−CCR7+CD27+), transitional memory (CD45RA−
CCR7−CD27+), effector memory (CD45RA−CCR7−CD27−), and terminally differentiated
effector memory (TEMRA; CD45RA+CCR7−CD27−) within the total CD4 or CD8 T cell popu-
lation. T cell activation was defined as the proportion of cells that were positive for both CD38
and HLA-DR within the total CD4 or CD8 T cell population. T cell exhaustion was defined as
the proportion of PD1 positive cells within the total CD4 or CD8 T cell population. Terminally
differentiated T cells were defined as proportion of CD57 positive cells within the total CD4 or
CD8 T cells population, the proportion of cells negative for both CD27 and CD28 within the
total CD4 or CD8 T-cells population, or the proportion of CD57 positive within the CD28−
CD4+ or CD28−CD8+ T cell populations. The following directly conjugated monoclonal anti-
bodies were used for cell surface marker staining: CD3 V500, CD4 PE-Cy7, HLA-DR Fitc,
CD38 PE, CD28 PerCP Cy5.5, CD45RA PE-Cy7, CD8 Pacific Blue, CD57 APC, CCR7 PE,
CD27 PerCP Cy5.5 (BD Biosiences, San Jose, CA, USA), CD27 APCeFluor780, CD4 APC
eFluor780, and PD-1 PE (eBioscience, San Diego, CA, USA). Fluorescence was measured with
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the FACS Canto II (BD Biosciences). The proportion of cells expressing each marker were
determined using FlowJo 7.6 (TreeStar, Ashland, OR, USA). The gating strategy is displayed in
the supplementary information (S1 Fig).
CMV antibody titers
CMV specific IgG levels are believed to be a surrogate marker of CMV reactivation and con-
current immune response to control infection [31]. Thus, increased CMV total antibody and
high avidity titers indicate recurrent CMV antigen exposure, whereas CMV high avidity titers
are also indicative of increased antibody maturation. CMV total antibody titers and high
avidity antibody titers were measured by ELISA-VIDITEST anti-CMV-IgG and IgG avidity
(VIDIA, Praha, Czech republic) according to the manufacturer’s instruction. For quantifica-
tion a standard curve was prepared by serial dilution of plasma from a known CMV seroposi-
tive individual.
Statistical analysis
Differences in subject characteristics between HIV-positive, HIV-negative and blood bank
donors were assessed using Student’s T test, Mann-Whitney U test, or Pearson Chi-square
test, as appropriate. Associations of immunological markers with study group (HIV-positive,
HIV-negative, blood bank donors) and CMV serostatus were evaluated using multivariable
linear regression adjusted for age and gender. In the sub-group of participants who were CMV
seropositive, we then considered the association of each immunological marker with group
and i) CMV total IgG and ii) CMV high avidity IgG, with the same adjustments. Some out-
comes were transformed to attain normality as indicated in the table. Unstandardized coeffi-
cient (B) indicates the difference in the outcome (immunological markers) with respect to the
variables (study group, CMV infection), and are given in the table. Uncorrected p values are
given in the tables and the required p value for significance after Bonferroni adjustment for
multiple testing is indicated. Analyses were performed in IBM SPSS Statistics for Windows
v.23 (IBM, Armonk, NY, USA) and GraphPad Prims 6 (GraphPad, La Jolla, CA, USA).
Results
Baseline characteristics of COBRA participants and blood bank donors
HIV-positive individuals had a median (IQR) age of 58.5 (53.5–63.5) years and HIV-negative
controls had a median (IQR) age of 59 (53–63.5) years. The groups were representative of the
main COBRA cohort study (HIV-positive individuals: 93.3% male, 86.6% MSM, 12.0% of Afri-
can descent; HIV-negative controls: 92.4% male, 79.8% MSM, 2.6% of African descent). HIV-
positive individuals had been diagnosed with HIV for a mean (standard deviation) of 13.9
(4.8) years ago, had been on ART for a mean (standard deviation) of 12.2 (4.7) years and had
spent a median (IQR) of 8.0 (5.3–10.9) years with an undetectable plasma viral load (Table 1).
Whilst the percentage of males did not differ significantly between the HIV-positive and HIV-
negative COBRA participants, it was significantly lower in the group of blood bank donors.
HIV-positive and HIV-negative COBRA participants were more often (co-)infected with
CMV and HCV as compared to the blood bank donors, whereas HIV-positive COBRA partici-
pants were more often infected with CMV, HBV and HCV when compared to HIV-negative
COBRA participants (Table 1). HIV-positive COBRA participants, despite long-term suppres-
sion of HIV-replication by ART, exhibited incomplete CD4+ T-cell restoration and elevated
CD8+ T-cell counts compared to HIV-negative COBRA participants, as reflected by lower
CD4 counts, higher CD8 counts and an inverted CD4:CD8 T-cell ratio (Table 1).
Terminally differentiated T-cells in HIV+ on ART
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T cell activation and exhaustion in COBRA participants and blood bank
donors
The percentages of activated (HLA-DR+CD38+) CD4 T cells and exhausted (PD1+) CD4 T
cells were higher in ART-treated HIV-positive COBRA participants compared to both cohorts
of HIV-negative participants (Table 2, Fig 1A and 1B). Interestingly, the percentage of PD1+
expressing CD4 T cells was higher in both the HIV-positive and HIV-negative COBRA partici-
pants when compared to the blood bank donors (Fig 1B and Table 2). The percentage of acti-
vated (HLA-DR+CD38+) CD8 T cells was higher in the HIV-positive COBRA participants but
not in the HIV-negative COBRA participants when compared to the blood bank donors (Fig
1C and Table 2). No differences were observed in the percentage of exhausted (PD1+) CD8 T
cells between the three groups (Fig 1D and Table 2).
T cell differentiation in COBRA participants and blood bank donors
In the CD4 compartment, the percentage of naïve cells (CD45RA+CD27+CCR7+) was lower in
the HIV-positive COBRA participants compared to the HIV-negative COBRA participants, but
no differences were observed in the percentage of central memory (CD45RA−CCR7+CD27+),
transitional memory (CD45RA−CCR7−CD27+), effector memory (CD45RA−CCR7−CD27−)
and TEMRA cells (CD45RA+CCR7−CD27−) (Table 2). When compared to the blood bank
Table 1. Baseline characteristics HIV-positive and HIV-negative COBRA participants and blood bank donors.
HIV-positive
n = 40
HIV-negative
n = 40
HIV-positive vs HIV-
negative
Blood bank
donors n = 35
HIV-positive vs
BBD
HIV-negative vs
BBD
n (%) or median
(IQR)
n (%) or median
(IQR)
p value1 n (%) or median
(IQR)
p value1 p value1
Age (Years) 58.5 (53.5–63.5) 59.0 (53.0–64.5) 0.9 58 (52.0–65.0) 0.5 0.5
Male sex 36 (90.0%) 37 (92.5%) 0.7 18 (51.4%) < .001 < .001
African descent 5 (12.5%) 1 (2.5%) 0.09 n.a.
MSM 32 (80.0%) 30 (75.0%) 0.8 n.a.
CMV 38 (95.0%) 31 (77.5%) 0.02 8 (22.9%) < .001 < .001
anti-CMV IgG 50.9 (23.5–108.6) 23.9 (13.8–87.8) 0.03 11.3 (10.2–16.8) 0.002 0.09
High avidity anti-CMV IgG 30.7 (13.0–57.0) 13.3 (8.2–39.7) 0.048 10.7 (10.0–13.2) 0.046 0.4
HBV 21 (52.5%) 7 (17.5%) 0.001 n.a.
Cleared 18 (45.0%) 7 (17.5%) 0.008 n.a.
Chronic 3 (7.5%) 0 (0%) 0.08 0 (0%) 0.1 n.d.
HCV (chronic and acute) 6 (15%) 0 (0%) 0.01 0 (0%) 0.02 n.d.
CD4 counts, cells/μl 589 (470–800) 961 (759–1233) < .001 n.a.
CD8 counts, cells/μl 762 (636–1029) 488 (364–621) < .001 n.a.
CD4:CD8 ratio 0.80 (0.61–1.13) 1.95 (1.33–2.83) < .001 n.a.
CD4 nadir, cells/μl 180 (60–180)
Years since HIV diagnosis 13.9 (9.1–18.7)
Years since ART 12.2 (7.9–16.9)
Years undetectable plasma viral
load (<200 c/ml)2
8.0 (5.3–10.9)
1 p value calculated using Student’s t-test, Mann-Whitney U test or Chi-Square test, or Wilcoxon’s rank-sum test where applicable.
2 The threshold was set at 200 c/ml to exclude incidental viral blips from the period in which plasma viral load was detectable.
Abbreviations: HIV, human immunodeficiency virus; BBD, blood bank donors n.a., not available; n.d., not determined; IQR, interquartile range; MSM, men
who have sex with men; CMV, Cytomegalovirus; HBV, hepatitis B virus; HCV, hepatitis C virus; ART, antiretroviral therapy.
https://doi.org/10.1371/journal.pone.0183357.t001
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donors, we observed that HIV-positive and HIV-negative COBRA participants had a higher
percentage of effector memory cells (CD45RA−CCR7−CD27−), whereas an additional increase
in the percentage of TEMRA cells (CD45RA+CCR7−CD27−) was observed in the HIV-negative
COBRA participants (Table 2).
Within the CD8 compartment, the percentage of effector memory cells (CD45RA−CCR7−
CD27−) was higher in HIV-positive COBRA participants compared to the HIV-negative
COBRA participants, whereas no differences were observed in the other populations (Table 2).
When compared to the blood bank donors, HIV-positive and HIV-negative COBRA partici-
pants had a lower percentage of naïve CD8 cells (CD45RA+CD27+CCR7+). The percentage of
effector memory cells (CD45RA−CCR7−CD27−) was higher in HIV-positive, while the per-
centage of transitional memory (CD45RA−CCR7−CD27+) was lower and TEMRA cells
Table 2. T cell activation, exhaustion and differentiation in HIV-positive and HIV-negative COBRA participants and blood bank donors.
Markers HIV-positive median
(IQR)
HIV-negative median
(IQR)
HIV-pos vs HIV-
neg
p value1
BBD median (IQR) BBD vs HIV-
pos
p value1
BBD vs HIV-
neg
p value1
CD4+ T cells
% HLA-DR+CD38+ of CD4+ T cells2 2.58 (1.73–3.96) 1.56 (1.03–2.57) 0.001 2.09 (1.41–2.65) 0.06 0.06
% PD1+ of CD4+ T cells 2 6.77 (5.16–10.69) 6.2 (3.38–8.36) 0.015 4.2 (2.73–5.03) 2.0E-06 0.03
% CD57+ of CD4+ T cells 2 12.14 (6.32–18.43) 12.21 (7.01–19.31) 0.8 4.73 (2.91–8.47) 3.2E-04 0.001
% CD27−CD28− of CD4+ T cells 2 4.76 (1.14–8.49) 6.03 (1.46–12.25) 0.8 0.19 (0.05–0.57) 1.0E-06 3.0E-06
% CD57+ of CD4+CD28− T cells 58.88 (37.64–81.46) 79.59 (45.93–85.51) 0.07 32.23 (15.29–63.46) 0.015 2.9E-04
% CD45RA+CCR7+CD27+ of CD4+ T
cells 4
11.4 (4.9–20.01) 18.54 (9.62–29.43) 0.017 23.37 (13.06–40.8) 9.4E-05 0.1
% CD45RA−CCR7+CD27+ of CD4+ T
cells 4
16.6 (11.33–23.1) 15.99 (10.74–22.9) 0.5 19.4 (11.44–22.44) 0.5 0.4
% CD45RA−CCR7−CD27+ of CD4+ T
cells 2
23.99 (21.17–33.27) 23.87 (18.75–27.1) 0.3 27.16 (19.81–33.86) 0.8 0.1
% CD45RA−CCR7−CD27− of CD4+ T
cells 2
11.85 (7.57–24.88) 10.55 (6.57–18.93) 0.4 6.97 (3.87–9.37) .001 0.046
% CD45RA+CCR7−CD27− of CD4+ T
cells 2
0.93 (0.55–2.52) 2.05 (1.06–4.41) 0.1 0.74 (0.3–1.33) 0.2 0.039
CD8+ T cells
% HLA-DR+CD38+ of CD8+ T cells 2 7.46 (4.54–10.8) 5.6 (3.29–9.65) 0.2 4.05 (2.66–5.68) 9.7E-05 0.051
% PD1+ of CD8+ T cells 2 19.58 (14.06–23.91) 16.08 (11.56–24.02) 0.2 15.79 (12.42–20.41) 0.4 0.9
% CD57+ of CD8+ T cells 50.6 (36.81–57.2) 45.08 (35.57–57.44) 0.8 30.4 (14.91–42.4) .009 .031
% CD27−CD28− of CD8+ T cells 38.1 (24.8–46.4) 36.4 (22.55–50.05) 0.7 12.2 (5.56–20.7) 4.5E-06 3.4E-04
% CD57+ of CD8+CD28− T cells 3 75.75 (67.06–80.98) 79.31 (74.03–85.81) 0.045 61.4 (49.4–83.37) 0.6 0.037
% CD45RA+CCR7+CD27+ of CD8+ T
cells 4
6.31 (3.67–10.12) 8.36 (4.19–15.23) 0.08 18.46 (9.85–30.48) 1.3E-05 0.025
% CD45RA−CCR7+CD27+ of CD8+ T
cells 2
3.71 (2.81–5.69) 4.47 (1.87–7.61) 1.0 5.34 (3.08–8.79) 0.8 1.0
% CD45RA−CCR7−CD27+ of CD8+ T
cells 4
26.8 (19.12–33.19) 20.72 (15.22–27.11) 0.06 34.49 (29.81–42.38) 0.2 0.003
% CD45RA−CCR7−CD27− of CD8+ T
cells 2
19.18 (14.37–29.89) 12.9 (9.13–19.46) 0.006 9.23 (5.79–15.22) 0.001 0.3
% CD45RA+CCR7−CD27− of CD8+ T
cells 4
19.17 (12.96–24.8) 19.18 (11.26–36.78) 0.3 8.88 (5.44–20.4) 0.1 0.047
1 Multivariable linear regression, corrected for age and gender. Uncorrected p values are given. Bonferroni adjustment for multiple testing required a p value
of <0.0025 for significance.
2 LOG transformed to obtain normality.
3 acrsine transformed to obtain normality.
4 square root transformed to obtain normality
Abbreviations: HIV, human immunodeficiency virus; BBD, blood bank donors; IQR, interquartile range.
https://doi.org/10.1371/journal.pone.0183357.t002
Terminally differentiated T-cells in HIV+ on ART
PLOS ONE | https://doi.org/10.1371/journal.pone.0183357 August 14, 2017 6 / 17
(CD45RA+CCR7−CD27−) higher in HIV-negative COBRA participants as compared to the
blood bank donors (Table 2).
Percentage of terminally differentiated T cells is increased in COBRA
participants compared to blood bank donors
No significant differences in the percentages of terminally differentiated T cells between the
HIV-positive and HIV-negative COBRA participants were observed (Fig 2A and 2B and
Fig 1. CD4 and CD8 T cell activation and exhaustion in HIV-positive and HIV-negative COBRA participants, and
blood bank donors. (a) The percentage of activated (HLA-DR+CD38+) and (b) exhausted (PD-1+) CD4+ T cells within the
CD4+ T-cell population. (c) The percentage of activated (HLA-DR+CD38+) and (d) exhausted (PD-1+) T cells within the
CD8+ T-cell population. Significance was assessed with multivariable linear regression, corrected for age and gender.
HIV+, HIV-positive; HIV-, HIV-negative; BBD, blood bank donors.
https://doi.org/10.1371/journal.pone.0183357.g001
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Table 2). Strikingly, a strong increase in the percentages of both terminally differentiated CD4
and CD8 T cells (CD57+ and CD27−/CD28−) was observed both when HIV-positive or HIV-
negative COBRA participants were compared to blood bank donors (Fig 2A and 2B and
Table 2). In addition, we analysed the percentage of CD57 expressing cells within the
CD28−CD8+ T-cells or CD28−CD4+ T cells as these cells have been shown to accumulate
upon chronic antigenic stimulation by viral pathogens [25]. The percentage of CD57 express-
ing cells within the CD28−CD4+ T cell population was not different between HIV-positive and
HIV-negative COBRA participants (Fig 2C and Table 2). However when compared to the
blood bank donors, the percentage of CD57 expressing cells within the CD28−CD4+ T cells
was higher in both the HIV-positive and HIV-negative COBRA participants (Fig 2C and
Table 2). The percentage of CD57 expressing cells within the CD28−CD8+ T cells was lower in
HIV-positive COBRA participants as compared to HIV-negative COBRA participants (Fig 2D
and Table 2). Blood bank donors have lower levels of CD57 expressing cells within the
CD28−CD8+ T cells when compared to HIV-negative COBRA participants, but not when
compared to HIV-positive COBRA participants (Table 2 and Fig 2D).
Fig 2. Terminally differentiated CD4 and CD8 T cells in HIV-positive and HIV-negative COBRA participants, and blood bank
donors. (a) The percentage of CD57+ and CD27−CD28− T cells within the CD4+ T cell population. (b) The percentage of CD57+ and
CD27−CD28− T cells within the CD8+ T cell population. (c) The percentage of CD57+ cells in the CD4+CD28− and (d) CD8+CD28−cell
population. Significance was assessed with multivariable linear regression, corrected for age and gender. HIV+, HIV-positive; HIV-, HIV-
negative; BBD, blood bank donors.
https://doi.org/10.1371/journal.pone.0183357.g002
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HIV-1 and CMV infection are both associated with T cell activation,
exhaustion and terminal differentiation
Multivariable linear regression analysis was performed to determine whether HIV-1 infection
and CMV infection (CMV serostatus) were independently associated with T cell activation,
exhaustion, and terminal differentiation of T cells. after adjusting for age and gender. Within
the CD4 compartment, both T cell activation (HLA-DR+CD38+) and T cell exhaustion (PD1+)
were higher in HIV-positive participants compared to HIV-negative COBRA participants,
whereas T cell exhaustion was lower in blood bank donors as compared to HIV-negative
COBRA participants (Table 3). Within the CD8 compartment, HIV infection was associated
with higher T cell exhaustion while CMV infection was independently associated with lower
CD8 T cell exhaustion (PD1+) (Table 3).
When we analysed markers of terminally differentiated T cells (CD57+ and CD27−CD28−)
we observed that the percentage of CD27−CD28− cells within CD4+ T cells was lower in both
HIV-positive COBRA participants and blood bank donors when compared to HIV-negative
COBRA participants (Table 3). Moreover, a strong association between a higher proportion of
terminally differentiated (CD57+ and CD27−CD28−) CD4 and CD8 T cells and CMV infection
was observed (Table 3). The percentages of CD57 expressing cells within the CD28−CD8+ T-
cells and CD28−CD4+ T cells were lower in HIV-positive COBRA participants, while a positive
association with CMV infection was observed.
CMV IgG titers are associated with terminal differentiation of T cells and
CD8 T cell exhaustion
Anti-CMV IgG antibodies were positive in 95% of the HIV-positive COBRA participants,
77.5% of the HIV-negative COBRA participants, and 22.9% of the blood bank donors. HIV-
positive COBRA participants had higher levels of total and high avidity CMV-IgG antibody
titers as compared to both the HIV-negative COBRA participants and the blood bank donors
(Table 1), confirming previous observations [30, 32, 33]. Increased CMV IgG levels are sugges-
tive of increased stimulation by CMV antigens, which may further contribute to T cell activa-
tion, exhaustion and terminal differentiation. Total CMV IgG was associated with higher CD4
T cell activation (HLA-DR+CD38+), and terminally differentiated (CD57+ and CD27−CD28−)
CD4 and CD8 T cells in CMV-positive individuals irrespective of HIV-1 infection (Table 3).
In this model, CD4 T cell activation (HLA-DR+CD38+), CD4 T cell exhaustion (PD1+) and
CD8 T cell exhaustion (PD1+) were still higher in HIV-positive participants, whereas the per-
centage of CD4+CD27−CD28− T cells, the percentage of CD57 expressing cells within the
CD28−CD8+ T-cells and CD28−CD4+ T cells were lower in HIV-positive COBRA participants
when compared to HIV-negative COBRA participants (Table 3). Similarly, CMV high avidity
IgG levels were associated with higher CD4 T cell activation, terminally differentiated (CD57+
and CD27−CD28−) CD8 T cells, the percentage of CD57+ cells within CD8+CD28− cells, but
not terminally differentiated (CD57+ and CD27−CD28−) CD4 T cells (Table 3).
Discussion
Despite effective ART, HIV-positive individuals are reported to have higher rates of age-asso-
ciated non-communicable diseases and a shorter average life expectancy compared to unin-
fected persons of the same age [3, 5, 7]. The increased morbidity and mortality in the HIV-1
infected population may be the result of several contributing factors such as ART toxicity,
chronic immune activation and immune dysfunction as well as a higher prevalence of tradi-
tional risk factors for these AANCC [8, 9]. Here we analysed markers of T cell activation,
Terminally differentiated T-cells in HIV+ on ART
PLOS ONE | https://doi.org/10.1371/journal.pone.0183357 August 14, 2017 9 / 17
Table 3. Multivariable analyses of the association between HIV-1 infection, CMV serostatus, as well as CMV total and high avidity IgG titers, and T
cell activation, exhaustion and terminal differentiation in HIV-positive and HIV-negative COBRA participants and blood bank donors.
Complete population adjusted for
CMV serostatus1
CMV positive participants adjusted for
CMV Total IgG2
CMV positive participants adjusted
for CMV High Avidity IgG2
Activation and Exhaustion B (95% CI)5 p value B (95% CI) 5 p value B (95% CI) 5 p value
% HLA-DR+CD38+ of CD4+ T cells3 Group HIV-neg (ref)
HIV-pos 0.21 (0.10–0.32) 0.0003 0.18 (0.06–0.31) 0.005 0.19 (0.06–0.31) 0.003
BBD 0.10 (-0.038–0.24) 0.2 0.07 (-0.15–0.30) 0.5 0.07 (-0.15–0.29) 0.5
CMV 0.01 (-0.12–0.13) 0.9 0.001 (0.0003–0.002) 0.006 0.002 (0.0007–0.003) 0.003
% PD1+ of CD4+ T cells3 Group HIV-neg (ref)
HIV-pos 0.13 (0.02–0.24) 0.02 0.15 (0.04–0.26) 0.01 0.16 (0.04–0.27) 0.007
BBD -0.14 (-0.27–0.01) 0.04 -0.06 (-0.26–0.14) 0.6 -0.06 (-0.26–0.14) 0.5
CMV -0.002 (-0.12–0.12) 1.0 0.0003 (-0.0003–0.001) 0.3 0.0002 (-0.0009–0.001) 0.7
% HLA-DR+CD38+ of CD8+ T cells3 Group HIV-neg (ref)
HIV-pos 0.07 (-0.05–0.19) 0.3 0.03 (-0.11–0.17) 0.7 0.03 (-0.10–0.17) 0.6
BBD -0.11 (-0.26–0.03) 0.1 -0.23 (-0.47–0.01) 0.06 -0.23 (-0.48–0.009) 0.06
CMV 0.07 (-0.07–0.21) 0.3 0.00005 (-0.0003–0.001) 0.2 0.0008 (-0.0005–0.002) 0.2
% PD1+ of CD8+ T cells3 Group HIV-neg (ref)
HIV-pos 0.08 (-0.008–0.17) 0.07 0.11 (0.03–0.19) 0.008 0.11 (0.03–0.19) 0.007
BBD -0.07 (-0.18–0.04) 0.2 0.01 (-0.13–0.15) 0.9 0.01 (-0.13–0.15) 0.9
CMV -0.14 (-0.24–0.04) 0.006 -0.0006 (-0.0005–0.0004) 0.8 -0.0002 (-0.001–0.0006) 0.7
Terminal differentiation
% CD57+ of CD4+ T cells3 Group HIV-neg (ref)
HIV-pos -0.09 (-0.23–0.05) 0.2 -0.14 (-0.30–0.02) 0.08 -0.14 (-0.29–0.02) 0.09
BBD -0.13 (-0.30–0.04) 0.1 -0.16 (-0.44–0.13) 0.3 -0.16 (-0.45–0.12) 0.3
CMV 0.36 (0.20–0.51) 1.3E-05 0.001 (0.00003–0.002) 0.04 0.001 (-0.0001–0.003) 0.07
% CD27-CD28- of CD4+ T cells3 Group HIV-neg (ref)
HIV-pos -0.28 (-0.54–0.03) 0.03 -0.33 (-0.62–0.05) 0.02 -0.32 (-0.61–0.03) 0.03
BBD -0.35 (-0.66–0.04) 0.03 -0.49 (-1.00–0.03) 0.06 -0.49 (-1.01–0.02) 0.06
CMV 1.32 (1.03–1.61) 5.2E-15 0.002 (0.00005–0.003) 0.04 0.003 (-0.0002–0.006) 0.06
% CD57+ of CD8+ T cells Group HIV-neg (ref)
HIV-pos -1.89 (-8.07–4.28) 0.5 -3.77 (-10.52–2.99) 0.3 -3.63 (-10.25–2.99) 0.3
BBD -1.13 (-8.82–6.56) 0.7 -5.91 (-17.90–6.08) 0.3 -6.03 (-17.87–5.81) 0.3
CMV 16.02 (8.97–23.07) 1.6E-05 0.05 (0.016–0.09) 0.006 0.10 (0.04–0.17) 0.003
% CD27-CD28- of CD8+ T cells Group HIV-neg (ref)
HIV-pos -2.64 (-8.65–3.37) 0.4 -6.07 (-12.98–0.85) 0.09 -5.72 (-12.59–1.15) 0.1
BBD -5.22 (-12.70–2.27) 0.2 -15.21 (-27.49–2.94) 0.02 -15.40 (-27.68–3.12) 0.02
CMV 21.38 (14.51–28.23) 1.2E-08 0.05 (0.02–0.09) 0.007 0.09 (0.03–0.16) 0.008
% CD57+ of CD4+CD28- T cells Group HIV-neg (ref)
HIV-pos -17.67 (-27.73–7.61) 0.001 -18.31 (-29.31–7.32) 0.001 -18.67 (-29.45–7.88) 0.001
BBD -7.59 (-20.13–4.95) 0.2 -7.09 (-26.61–12.42) 0.5 -7.05 (-26.335–12.24) 0.5
CMV 39.74 (28.25–51.24) 4.5E-10 0.04 (-0.03–0.10) 0.2 0.10 (-0.01–0.20) 0.08
% CD57+ of CD8+CD28- T cells4 Group HIV-neg (ref)
HIV-pos -0.10 (-0.18–0.01) 0.03 -0.10 (-0.19–0.02) 0.02 -0.10 (-0.19–0.02) 0.02
BBD -0.05 (-0.16–0.06) 0.3 -0.07 (-0.23–0.08) 0.3 -0.07 (-0.23–0.08) 0.3
CMV 0.13 (0.03–0.23) 0.01 0.0004 (-0.0001–0.0009) 0.1 0.001 (0.00007–0.002) 0.04
1 Multivariable linear regression adjusted for age and gender in HIV-positive (n = 40), HIV-negative (n = 40) and BBD (n = 35). Uncorrected p values are
given. Bonferroni adjustment for multiple testing required a p value of <0.005 for significance.
2 Multivariable linear regression adjusted for age and gender in HIV-positive (n = 38), HIV-negative (n = 31) and BBD (n = 8) infected with CMV. Uncorrected
p values are given. Bonferroni adjustment for multiple testing required a p value of <0.005 for significance.
3 LOG transformed to obtain normality.
4 acrsine transformed to obtain normality.
5Unstandardized coefficient (B) indicates the difference in the outcome (immunological markers) with respect to the variables (study group, CMV infection).
For example, B is the increase in LOG transformed % of HLA-DR+CD38+ of CD4+ T cells in a HIV-positive individual as compared to a HIV-negative
participant.
Abbreviations: HIV, human immunodeficiency virus; BBD, blood bank donors; B, unstandardized regression coefficient; CI, confidence interval; CMV,
Cytomegalovirus; IgG, Immunoglobulin G
https://doi.org/10.1371/journal.pone.0183357.t003
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exhaustion, and differentiation in a cohort of HIV-positive adults who were on apparently
effective ART and compared these to data from adults who were comparable for age, lifestyle
and demographic factors (COBRA) and a cohort age matched blood bank donors. HIV-posi-
tive COBRA participants showed incomplete immune recovery as reflected by lower CD4 T
cell counts and higher CD8 T cell counts than observed in either well-matched or just age-
matched uninfected controls. Furthermore, a higher percentage of activated and exhausted
CD4 cells, a lower percentage of CD4 naïve cells and higher percentage of CD8 effector mem-
ory cells were observed when compared to HIV-negative COBRA participants which is
broadly consistent with previous studies [30, 34–40]. In contrast, measures of terminally differ-
entiated T cells (CD57+ and CD27− CD28−), did not differ between the treated HIV-positive
and HIV-negative COBRA participants, confirming previous observations [17, 30], but con-
tradicting other studies [8, 13, 25, 27]. Collectively, these data provide strong support for the
concept that certain HIV-mediated immunologic perturbations (e.g., low CD4/CD8 ratio,
shift towards more differentiated memory cell types, high PD-1 expression) do indeed persist
indefinitely during ART, while other markers more typically associated with terminal differen-
tiation and senescence may normalize, at least compared to levels observed in well-matched
persons who lack HIV but have other risk factors, particularly CMV infection.
Strikingly, the percentages of activated CD8 T cells, exhausted CD4 T cells and terminally
differentiated CD4 and CD8 T cells were higher in both HIV-positive and HIV-negative
COBRA participants when compared to the general populations (e.g., the blood bank donors).
HIV-positive and negative COBRA participants are more often infected with CMV when com-
pared to the blood bank donors which may be due to the high number of men-who-have-sex-
with-men in the COBRA participants. Multivariable analysis showed that HIV-1 infection is
independently associated with CD4 T cell activation and T cell exhaustion but not with termi-
nally differentiated T cells (CD57+ and CD27−CD28−). CMV infection was strongly associated
with increased proportion of terminally differentiated T cells and may at least partially explain
the higher levels of terminally differentiated T cells in the HIV-positive and HIV-negative
COBRA participants. This is in line with previous publications in which CMV infection was
strongly associated with increased terminal differentiation of T cells and CD8 T cell exhaustion
[13, 15, 17, 28, 29]. However, no association of CMV infection with T cell activation was
observed which is in contrast with previous studies [41–43]. HIV-positive individuals in our
study are considered to be successfully treated, which is reflected in the high CD4 counts and
relatively high CD4:CD8 ratios. Furthermore, they have a relative low % of activated CD8 cells
(median 7,5% CD8+HLA-DR+CD38+) as compared to the other studies (15–20% CD8+HLA-
DR+CD38+) [41–43], and this might at least in part explain the differences between the studies.
We did however observe that higher CMV IgG titers were associated with higher CD4 T cell
activation in the CMV-positive participants.
HIV-positive COBRA participants had increased levels of CMV specific IgG when com-
pared to HIV-negative COBRA participants and blood bank donors, confirming previous
observations [30, 32, 33]. CMV specific IgG levels are considered a surrogate marker of CMV
reactivation and concurrent immune response to control infection, and high levels are associ-
ated with ageing and increased morbidity and mortality in both the general population and
HIV-positive individuals [30–33, 44–46]. Total CMV IgG was independently associated with
the presence of a higher proportion of terminally differentiated T cells and CD4 T cell activa-
tion, indicating that reactivation of CMV infection contributes substantially to terminal differ-
entiation of T cells and CD4 activation in treated HIV-positive individuals. This could suggest
that the high CMV prevalence combined with increased CMV reactivation may contribute to
the increased comorbidity burden that has been reported in treated HIV-positive individuals
[7]. Ageing and CMV infection are associated with terminal differentiation and proliferation
Terminally differentiated T-cells in HIV+ on ART
PLOS ONE | https://doi.org/10.1371/journal.pone.0183357 August 14, 2017 11 / 17
of CD8+CD28−CD57+ effector memory cells, however HIV-1 has been shown to inhibit
the terminal differentiation of these cells which is reflected in a decreased percentage of
CD28−CD8+ T-cells expressing CD57 [17, 18]. In line with these findings we observed that
HIV-1 infection was independently associated with a decrease in the percentage of CD57
expressing cells within the CD28−CD8+ T cells, whereas CMV infection was independently
associated with an increased percentage of these cells.
Cigarette smoking is known to have an impact on different immune functions, with both
proinflammatory and immune suppressive effects having been described [47, 48]. For exam-
ple, increased levels of markers of inflammation (CRP, IL-6, D-dimer, sCD14), T cells activa-
tion (% HLA-DR+CD38+ of CD4 and CD8 cells), and decreased T cell function (% PD1+ CD4
and CD8 T cells) have been associated with smoking in HIV-infected individuals as well as in
the general population [49–52]. In the present study, data about cigarette smoking was only
available for the COBRA participants (HIV-positive and HIV-negative), and in this group no
association between smoking and T cell activation, T cell exhaustion, and terminal differentia-
tion of CD4 and CD8 cells was observed (data not shown). However, we cannot exclude that
the limited number of individuals analysed and the lack of data about cigarette smoking in the
BBD group might explain why previously reported associations between cigarette smoking
and T cell activation and function could not be confirmed [49, 51].
Due to its observational nature, our study does suffer from several limitations. Firstly,
although we attempted to identify independent effects of HIV and CMV, CMV infection was
highly prevalent in both groups of COBRA participants, reflecting the high numbers of MSM
in each group (for example, only 2 of the 40 HIV-positive participants were CMV-negative).
Thus our ability to differentiate the independent effects of the two viruses is limited. For this
reason, analyses of CMV IgG may provide greater discriminative ability. Secondly, we cannot
rule out the possibility that the effects seen were a consequence of other unmeasured differ-
ences between the groups rather than HIV and CMV infection per se. Finally, the small num-
bers in some of our groups, and the low prevalence of coinfection with HBV and HCV meant
that we were unable to assess the effects of coinfection with these viruses.
In conclusion, HIV-positive individuals on ART with long-term suppressed viraemia
exhibited incomplete immune recovery and increased immune activation/exhaustion com-
pared to HIV-negative controls matched for age, lifestyle and demographic factors. However,
no evidence for increased immune senescence as determined by the level of terminally differ-
entiated T cells, was observed when HIV-positive individuals on suppressive ART were com-
pared to appropriately selected controls matched for age, lifestyle and demographic factors. If
only blood donors or perhaps someone poorly matched convenience sample had been used
as controls one would have falsely concluded that HIV was independently associated with
increased proportion of terminally differentiated T cells. This illustrates the importance of
recruiting and utilising appropriate control populations for such studies.
Supporting information
S1 Fig. Gating strategy flow cytometry. A. Gating of CD4+ and CD8+ T cells. B. T cell differ-
entiation was defined as the proportion of naïve (N; CD45RA+CD27+CCR7+), central memory
(CM; CD45RA−CCR7+CD27+), transitional memory (TM; CD45RA−CCR7−CD27+), effector
memory (EM; CD45RA−CCR7−CD27−), and terminally differentiated effector memory
(TEMRA; CD45RA+CCR7−CD27−) within the total CD4 or CD8 T cell population. C. T
cell activation was defined as the proportion of cells that were positive for both CD38 and
HLA-DR within the total CD4 or CD8 T cell population. T cell exhaustion was defined as the
proportion of PD1 positive cells within the total CD4 or CD8 T cell population. Terminally
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differentiated T cells were defined as proportion of CD57 positive cells within the total CD4
or CD8 T cells population, the proportion of cells negative for both CD27 and CD28 within
the total CD4 or CD8 T-cells population, or the proportion of CD57 positive within the
CD28−CD4+ or CD28−CD8+ T cell population.
(PDF)
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